SG11202108964YA - Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator - Google Patents
Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulatorInfo
- Publication number
- SG11202108964YA SG11202108964YA SG11202108964YA SG11202108964YA SG11202108964YA SG 11202108964Y A SG11202108964Y A SG 11202108964YA SG 11202108964Y A SG11202108964Y A SG 11202108964YA SG 11202108964Y A SG11202108964Y A SG 11202108964YA SG 11202108964Y A SG11202108964Y A SG 11202108964YA
- Authority
- SG
- Singapore
- Prior art keywords
- relacorilant
- heteroaryl
- receptor modulator
- glucocorticoid receptor
- therapeutic uses
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962809327P | 2019-02-22 | 2019-02-22 | |
| US201962814441P | 2019-03-06 | 2019-03-06 | |
| US201962833517P | 2019-04-12 | 2019-04-12 | |
| PCT/US2020/019167 WO2020172501A1 (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108964YA true SG11202108964YA (en) | 2021-09-29 |
Family
ID=72141382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108964YA SG11202108964YA (en) | 2019-02-22 | 2020-02-21 | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11058670B2 (en) |
| EP (1) | EP3927345A4 (en) |
| JP (2) | JP2022523376A (en) |
| KR (1) | KR20210118971A (en) |
| CN (1) | CN113490496A (en) |
| AU (1) | AU2020226863B2 (en) |
| CA (1) | CA3131263C (en) |
| CL (1) | CL2021002145A1 (en) |
| IL (1) | IL285771A (en) |
| MX (1) | MX2021010135A (en) |
| SG (1) | SG11202108964YA (en) |
| WO (1) | WO2020172501A1 (en) |
| ZA (1) | ZA202105633B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| NZ776354A (en) | 2018-12-19 | 2023-03-31 | Corcept Therapeutics Inc | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| SG11202105765TA (en) * | 2018-12-21 | 2021-07-29 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators |
| CA3131263C (en) | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
| EP4157274A1 (en) * | 2020-05-27 | 2023-04-05 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates |
| WO2022134033A1 (en) * | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| TW202246260A (en) * | 2021-02-03 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | Fused azatricyclic derivatives, preparation method and medical use thereof |
| WO2023225282A1 (en) * | 2022-05-20 | 2023-11-23 | Corcept Therapeutics Incorporated | Methods of treating cushing's syndrome and liver disorders, and of reducing liver toxicity of other drugs administered to a patient |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (en) | 1954-11-30 | 1957-04-11 | ||
| IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (en) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | Carbazole derivatives and immunosuppressants |
| FR2697252B1 (en) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-trimethyl- (8abeta) -6-isoquinolineamine derivatives, process for their preparation and their use in therapy. |
| JPH09505030A (en) | 1993-08-06 | 1997-05-20 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | Hydroisoquinoline derivative |
| US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| AU756983B2 (en) | 1998-03-10 | 2003-01-30 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| AU2002258399A1 (en) | 2001-02-16 | 2002-09-19 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| US7238778B2 (en) | 2001-07-17 | 2007-07-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| ES2312598T3 (en) | 2001-07-23 | 2009-03-01 | Corcept Therapeutics, Inc. | METHOD TO AVOID WEIGHT PROFITS INDUCED BY ANTIPSYTICS. |
| WO2003061651A1 (en) | 2002-01-22 | 2003-07-31 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US8476254B2 (en) | 2002-07-02 | 2013-07-02 | Corcept Therapeutics, Inc. | Methods for treating psychosis associated with interferson-α therapy |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| KR20060090803A (en) | 2003-09-03 | 2006-08-16 | 와이어쓰 | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same |
| ES2313296T3 (en) | 2004-01-09 | 2009-03-01 | Corcept Therapeutics, Inc. | AZADECALINE GLUCOCORTICOID RECEPTOR MODULATORS. |
| EP1723174A1 (en) | 2004-02-26 | 2006-11-22 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health | A novel modulator of glucocorticoid receptor activities |
| NZ550362A (en) | 2004-03-09 | 2010-06-25 | Corcept Therapeutics Inc | Fused ring azadecalin glucocorticoid receptor modulators |
| KR100931411B1 (en) * | 2005-04-05 | 2009-12-10 | 에프. 호프만-라 로슈 아게 | 1H-pyrazole 4-carboxyamide, process for its preparation, and use thereof as 11beta-hydroxysteroid dehydrogenase |
| TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| EP1932843A1 (en) | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| US8309730B2 (en) | 2007-11-01 | 2012-11-13 | Bristol-Myers Squibb Company | Nonsteroidal compounds useful as modulators of glucocorticoid receptor AP-1 and/or NF-kappab acitivity and use thereof |
| KR20100102609A (en) | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| US20120022121A1 (en) | 2007-11-29 | 2012-01-26 | Dalton James T | Indoles, derivatives and analogs thereof and uses therefor |
| US20090156672A1 (en) | 2007-12-17 | 2009-06-18 | Northwestern University | Substituted Phenyl Aziridine Precursor Analogs as Modulators of Steroid Receptor Activities |
| WO2009155481A1 (en) | 2008-06-20 | 2009-12-23 | Gtx, Inc. | Metabolites of selective androgen receptor modulators and methods of use thereof |
| US20100135956A1 (en) | 2008-11-21 | 2010-06-03 | Auspex Pharmaceuticals, Inc. | Steroid modulators of progesterone receptor and/or glucocorticoid receptor |
| ES2531040T3 (en) | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Solid forms and preparation procedure |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| CA2806900A1 (en) | 2010-08-27 | 2012-03-01 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
| US9314473B2 (en) | 2011-02-03 | 2016-04-19 | Pop Test Oncology Limited Liability Company | System and method for diagnosis and treatment |
| RS57157B1 (en) | 2011-11-11 | 2018-07-31 | Gilead Apollo Llc | Acc inhibitors and uses thereof |
| PL3111950T3 (en) | 2012-02-24 | 2022-01-17 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| ES2597757T3 (en) | 2012-05-25 | 2017-01-20 | Janssen Sciences Ireland Uc | Uraciles pyroxexetane nucleosides |
| PL2854814T3 (en) * | 2012-05-25 | 2018-07-31 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| DK3848027T3 (en) * | 2013-11-25 | 2023-05-01 | Corcept Therapeutics Inc | Octahydro-fused azadecalinglucocorticoid receptor modulators |
| AU2016226451B2 (en) | 2015-03-02 | 2019-12-19 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonist and somatostatin analogues to treat ACTH-secreting tumors |
| US9829495B2 (en) | 2015-08-13 | 2017-11-28 | Corcept Therapeutics, Inc. | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
| WO2017151613A1 (en) | 2016-03-01 | 2017-09-08 | Corcept Therapeutics, Inc. | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| AU2018244928B2 (en) | 2017-03-31 | 2023-10-19 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US20180325891A1 (en) * | 2017-05-10 | 2018-11-15 | Corcept Therapeutics, Inc. | Octahydro azadecalin formulations |
| SG11202105765TA (en) * | 2018-12-21 | 2021-07-29 | Corcept Therapeutics Inc | Treatment of hypercoagulopathy in cushing's syndrome by administration of glucocorticoid receptor modulators |
| CA3131263C (en) | 2019-02-22 | 2024-01-02 | Corcept Therapeutics Incorporated | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator |
-
2020
- 2020-02-21 CA CA3131263A patent/CA3131263C/en active Active
- 2020-02-21 CN CN202080015826.9A patent/CN113490496A/en active Pending
- 2020-02-21 AU AU2020226863A patent/AU2020226863B2/en active Active
- 2020-02-21 US US16/797,421 patent/US11058670B2/en active Active
- 2020-02-21 SG SG11202108964YA patent/SG11202108964YA/en unknown
- 2020-02-21 WO PCT/US2020/019167 patent/WO2020172501A1/en unknown
- 2020-02-21 JP JP2021549571A patent/JP2022523376A/en active Pending
- 2020-02-21 MX MX2021010135A patent/MX2021010135A/en unknown
- 2020-02-21 KR KR1020217030352A patent/KR20210118971A/en not_active Application Discontinuation
- 2020-02-21 EP EP20759882.2A patent/EP3927345A4/en active Pending
-
2021
- 2021-06-09 US US17/343,524 patent/US11590113B2/en active Active
- 2021-08-10 ZA ZA2021/05633A patent/ZA202105633B/en unknown
- 2021-08-13 CL CL2021002145A patent/CL2021002145A1/en unknown
- 2021-08-22 IL IL285771A patent/IL285771A/en unknown
-
2022
- 2022-12-20 US US18/084,866 patent/US11684612B2/en active Active
-
2023
- 2023-05-09 US US18/144,979 patent/US20230346756A1/en active Pending
- 2023-10-12 JP JP2023176874A patent/JP2024009951A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022523376A (en) | 2022-04-22 |
| US11058670B2 (en) | 2021-07-13 |
| US11684612B2 (en) | 2023-06-27 |
| IL285771A (en) | 2021-10-31 |
| US20230131372A1 (en) | 2023-04-27 |
| CA3131263A1 (en) | 2020-08-27 |
| KR20210118971A (en) | 2021-10-01 |
| EP3927345A4 (en) | 2022-12-21 |
| US20210338643A1 (en) | 2021-11-04 |
| US20230346756A1 (en) | 2023-11-02 |
| WO2020172501A1 (en) | 2020-08-27 |
| CA3131263C (en) | 2024-01-02 |
| US11590113B2 (en) | 2023-02-28 |
| CL2021002145A1 (en) | 2022-01-28 |
| MX2021010135A (en) | 2021-09-23 |
| EP3927345A1 (en) | 2021-12-29 |
| AU2020226863B2 (en) | 2023-04-06 |
| CN113490496A (en) | 2021-10-08 |
| ZA202105633B (en) | 2023-02-22 |
| JP2024009951A (en) | 2024-01-23 |
| AU2020226863A1 (en) | 2021-08-12 |
| US20200268723A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285771A (en) | Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator | |
| IL282916A (en) | Fused ring compounds | |
| SG11202101372SA (en) | Fused ring compounds | |
| IL261654B (en) | Estrogen receptor modulators | |
| IL268319A (en) | Benzothiophene estrogen receptor modulators | |
| EP3074011A4 (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| EP3958874A4 (en) | A dota-binding chimeric antigen receptor for cellular therapy | |
| IL268263B (en) | Estrogen receptor modulators | |
| EP3956329C0 (en) | Solid forms of a toll-like receptor modulator | |
| IL278936A (en) | Pyrimidine cyclohexenyl glucocorticoid receptor modulators | |
| ZA201900877B (en) | Re-establishing a radio resource control connection | |
| IL304292A (en) | Chimeric receptor therapy | |
| IL284061A (en) | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound | |
| GB201911187D0 (en) | Receptor | |
| EP3902545A4 (en) | Novel salts of selective estrogen receptor degraders | |
| IL284973A (en) | Communication interface of a secure interface control | |
| GB201801831D0 (en) | Chimeric receptor | |
| EP4045503C0 (en) | Estrogen-related receptor alpha (err-alpha) modulators | |
| EP3828182A4 (en) | Fused ring lactam derivatives | |
| IL289575A (en) | Modulators of the nmda receptor | |
| GB201713391D0 (en) | Pharmaceutical hormone intermediates 11-ketone-16a, 17a-epoxy progesterone synthesis method | |
| EP3463342A4 (en) | Estrogen receptor modulator combinations | |
| TWI839788B (en) | C5a RECEPTOR MODULATORS | |
| ZA201802863B (en) | Soft gel capsule comprising a selective estrogen receptor modulator | |
| HUP1800327A1 (en) | Use of selective estrogen receptor modulators for treatment of kraurosis vulvae |